BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Good Laboratory Practices Software Upgrade for Biotage® Extrahera™

  Biotage AB, is pleased to announce the launch of a Good Laboratory Practices software upgrade for Biotage® Extrahera™, their flagship automated sample preparation instrument for Supported Liquid Extraction, Solid Phase Extraction, Phospholipid Depletion and Protein Precipitation.

  February 20, 2020

   · 

  2 min read
• Business

  DuPont Nutrition & Biosciences Enters into Collaboration with Microbiome Specialist MRM Health

  MRM Health also announced that it raised more than €14m to advance its clinical and preclinical development programs in the field of microbiome-based therapeutics with partner participation.

  February 20, 2020

   · 

  8 min read
• Business

  MRM Health enters into its first industry collaboration with DuPont Nutrition & Biosciences and boosts its development with an investment of more than €14 million to redefine microbiome-based therapeutics

  Microbiome specialist MRM Health enters into its first industry collaboration with DuPont Nutrition & Biosciences in the field of metabolic diseases.

  February 20, 2020

   · 

  11 min read
• 

  Drug Development

  Teva’s Austedo Fails a Pair of Tourette Syndrome Trials

  Teva’s deutetrabenazine for the treatment of tics in pediatric patients with moderate to severe Tourette Syndrome did not meet the primary endpoint in the Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials.

  February 20, 2020

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Immatics and GSK Team Up to Develop and Advance T-Cell Therapies

  Immatics is eligible for more than $550 million in various commercial milestone payments for each product as well as additional royalties.

  February 20, 2020

   · 

  2 min read

   · 

  Mark Terry
• 

  BioCapital

  Research Roundup: Misfolding DNA and Type 1 Diabetes and More

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

  February 20, 2020

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  A Look at Kazia’s Business Model with CEO James Garner

  Kazia Therapeutics is company focused on developing anti-cancer drugs.

  February 20, 2020

   · 

  2 min read

   · 

  Gina Hagler
• 

  Do You Have Imposter Syndrome? 7 Ways to Overcome It

  Learning to love and accept your authentic self will go a long way toward quashing Imposter Syndrome.

  February 20, 2020

   · 

  3 min read

   · 

  Katharine Hansen, PhD
• Drug Development

  Recardio Completes Interim Analysis of Phase 2 in AMI

  Recardio Inc., a clinical-stage life science company, announced that it has completed an interim analysis of its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction.

  February 20, 2020

   · 

  2 min read
• BioMidwest

  Nurocor and CSG Partner to Create a New Solution for CDISC Efficiencies

  The companies combine leading metadata technology with CDISC Subject Matter Experts

  February 20, 2020

   · 

  2 min read